Sinusitis - Pipeline Review, H1 2016

Published: Mar, 2016 | Pages: 80 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Sinusitis - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Sinusitis - Pipeline Review, H1 2016', provides an overview of the Sinusitis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Sinusitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Sinusitis
- The report reviews pipeline therapeutics for Sinusitis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Sinusitis therapeutics and enlists all their major and minor projects
- The report assesses Sinusitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Sinusitis

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Sinusitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sinusitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Sinusitis Overview 7
Therapeutics Development 8
Pipeline Products for Sinusitis - Overview 8
Sinusitis - Therapeutics under Development by Companies 9
Sinusitis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Sinusitis - Products under Development by Companies 13
Sinusitis - Companies Involved in Therapeutics Development 14
Amgen Inc. 14
F. Hoffmann-La Roche Ltd. 15
Knopp Biosciences LLC 16
Merck & Co., Inc. 17
Oticpharma Ltd 18
Paratek Pharmaceuticals, Inc. 19
Regeneron Pharmaceuticals, Inc. 20
Therabron Therapeutics, Inc. 21
Sinusitis - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
AMG-282 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CG-201 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
dexpramipexole dihydrochloride - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
dupilumab - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
fluticasone propionate - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
omadacycline tosylate - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
omalizumab - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
P-008 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
PCL-1404 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Qi-117 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecule for Sinusitis - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Small Molecules for Chronic Rhinosinusitis - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
solithromycin - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Sinusitis - Recent Pipeline Updates 54
Sinusitis - Dormant Projects 75
Sinusitis - Product Development Milestones 76
Featured News & Press Releases 76
Feb 03, 2016: Nasal polyps can be treated with medicine dupilumab 76
Feb 02, 2016: Sanofi and Regeneron Announce Publication of Positive Phase 2 Dupilumab Data in the Journal of the American Medical Association 76
Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets 77
Sep 30, 2014: Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 77
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 79
Disclaimer 80

List of Tables

Number of Products under Development for Sinusitis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Sinusitis - Pipeline by Amgen Inc., H1 2016 14
Sinusitis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 15
Sinusitis - Pipeline by Knopp Biosciences LLC, H1 2016 16
Sinusitis - Pipeline by Merck & Co., Inc., H1 2016 17
Sinusitis - Pipeline by Oticpharma Ltd, H1 2016 18
Sinusitis - Pipeline by Paratek Pharmaceuticals, Inc., H1 2016 19
Sinusitis - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 20
Sinusitis - Pipeline by Therabron Therapeutics, Inc., H1 2016 21
Assessment by Monotherapy Products, H1 2016 22
Number of Products by Stage and Target, H1 2016 24
Number of Products by Stage and Mechanism of Action, H1 2016 26
Number of Products by Stage and Route of Administration, H1 2016 28
Number of Products by Stage and Molecule Type, H1 2016 30
Sinusitis Therapeutics - Recent Pipeline Updates, H1 2016 54
Sinusitis - Dormant Projects, H1 2016 75